<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816607</url>
  </required_header>
  <id_info>
    <org_study_id>REK-2013/152</org_study_id>
    <secondary_id>REK-2013/152</secondary_id>
    <nct_id>NCT01816607</nct_id>
  </id_info>
  <brief_title>Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness</brief_title>
  <acronym>OxyTarget</acronym>
  <official_title>Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish a reliable method for detection of rectal cancer
      patients with aggressive tumor at risk of metastatic disease and death by functional MRI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of metastatic disease 5 years after rectal cancer treatment</measure>
    <time_frame>five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histomorphological response to preoperative chemoradiotherapy</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Detection of regional malignant lymph nodes at time of diagnosis</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">192</enrollment>
  <condition>Rectal Diseases</condition>
  <condition>Rectal Neoplasms</condition>
  <condition>Gastrointestinal Diseases</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Rectal cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>new functional magnetic resonance imaging (MRI) protocols</intervention_name>
    <description>diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI</description>
    <arm_group_label>Rectal cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, rectal cancer tissue, normal tissue, lymph nodes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rectal cancer patients referred to radical surgery, with or without preoperative
        chemoradiotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is willing and able to give full written consent according to the protocol
             approved by the Regional Ethics Committee.

          -  The patient has confirmed rectal cancer diagnosis and is scheduled to radical surgery
             alone or preoperative CRT followed by surgery.

          -  The patient is ≥ 18 years.

          -  The patient has no prior rectal cancer treatment.

          -  The patient has adequate renal function: creatinine clearance ≥ 60 ml/minute.

          -  The patient has signed the written informed consent according to the protocol approved
             by the Regional Ethics Committee.

        Exclusion Criteria:

          -  The patient has contraindication to MRI or MRI contrast agent according to clinical
             practice.

          -  The patient wants to withdraw for any reason during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathrine Røe Redalen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH. Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. Transl Oncol. 2019 Jan;12(1):76-83. doi: 10.1016/j.tranon.2018.09.010. Epub 2018 Sep 29.</citation>
    <PMID>30273860</PMID>
  </results_reference>
  <results_reference>
    <citation>Grøvik E, Redalen KR, Storås TH, Negård A, Holmedal SH, Ree AH, Meltzer S, Bjørnerud A, Gjesdal KI. Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor K(trans) and ΔR2* peak are significantly associated with lymph node metastasis. J Magn Reson Imaging. 2017 Jul;46(1):194-206. doi: 10.1002/jmri.25566. Epub 2016 Dec 21.</citation>
    <PMID>28001320</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>November 15, 2018</last_update_submitted>
  <last_update_submitted_qc>November 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Kathrine Røe Redalen</investigator_full_name>
    <investigator_title>Senior scientist</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Magnetic Resonance Imaging, Functional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Rectal Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

